Lysosomal Storage Disorders: Azafaros Takes Aim At Small Molecules

BioGeneration Ventures has given birth to a new European biotech, Azafaros, supplying seed funding for the development of a new generation of compounds to tackle rare metabolic disorders.  

SC1807_Seed-Funding_676427629_1200.jpg
Seed funding can be found to progress good ideas • Source: Shutterstock

Biotech and pharma companies have had some success in the past developing enzyme replacement therapies for lysosomal storage disorders such as Fabry disease and Gaucher disease, and a new European biotech company, Azafaros, spun out of Leiden University in the Netherlands, is aiming to build on that achievement by developing a new generation of agents for rare metabolic disorders.

The potential new class of therapeutic agents are small-molecule orally active, aza-sugar compounds which interfere with the metabolism of glycolipids...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.